Creative Medical Technology Holdings (CELZ) Share-based Compensation (2017 - 2025)
Creative Medical Technology Holdings (CELZ) posted quarterly Share-based Compensation of $3485.0 for Q1 2025, down 61.96% year-over-year from $9162.0 in Q1 2024, and down 61.96% quarter-over-quarter from $9162.0 in Q4 2024.
Creative Medical Technology Holdings (CELZ) Share-based Compensation (2017 - 2025) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Share-based Compensation for 7 consecutive years, with $3485.0 the latest figure, recorded in Q1 2025.
- In Q1 2025, Share-based Compensation fell 61.96% year-over-year to $3485.0; the TTM figure through Dec 2025 stood at $3485.0 (down 90.49% YoY), while the FY2025 annual figure was $3485.0, down 90.49% from the prior year.
- Share-based Compensation declined to $3485.0 in Q1 2025 per CELZ's latest filing, from $9162.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $383612.0 in Q3 2021 and bottomed at $3485.0 in Q1 2025.
- Historically, Share-based Compensation has averaged $49393.8 across 5 years, with a median of $9162.0 in 2022.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 97.61% — and 2023, when it climbed 1.1%.
- Creative Medical Technology Holdings' Share-based Compensation stood at $383612.0 in 2021, then sank by 97.61% to $9162.0 in 2022, then changed by 0.0% to $9162.0 in 2023, then changed by 0.0% to $9162.0 in 2024, then tumbled by 61.96% to $3485.0 in 2025.
- Business Quant data shows CELZ's Share-based Compensation at $3485.0 in Q1 2025, $9162.0 in Q4 2024, and $9162.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Creative Medical Technology Holdings | 1.83 Mn | 1.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 3,485.00 |
| Mar 31, 2025 | 3,485.00 |
| Dec 31, 2024 | 9,162.00 |
| Dec 31, 2024 | 9,162.00 |
| Sep 30, 2024 | 9,162.00 |
| Sep 30, 2024 | 9,162.00 |
| Jun 30, 2024 | 9,162.00 |
| Jun 30, 2024 | 9,162.00 |
| Mar 31, 2024 | 9,162.00 |
| Mar 31, 2024 | 9,162.00 |
| Dec 31, 2023 | 9,162.00 |
| Dec 31, 2023 | 9,162.00 |
| Sep 30, 2023 | 9,162.00 |
| Sep 30, 2023 | 9,162.00 |
| Jun 30, 2023 | 9,162.00 |
| Jun 30, 2023 | 9,162.00 |
| Mar 31, 2023 | 9,162.00 |
| Mar 31, 2023 | 9,162.00 |
| Dec 31, 2022 | 9,162.00 |
| Dec 31, 2022 | 9,162.00 |